The business model of Masimo Corp focuses on providing innovative noninvasive monitoring technologies. Masimo develops and manufactures a wide range of medical devices and sensors to improve patient outcomes and reduce healthcare costs. The company's flagship product, Masimo SET®, revolutionized pulse oximetry by offering accurate measurements even in challenging conditions. With a dedication to patient safety and care, Masimo Corp combines advanced signal processing and sensor technology to deliver reliable monitoring solutions to healthcare professionals. Through their product portfolio, Masimo Corp aims to enhance patient care and promote efficiency in the healthcare industry.

Masimo Corp is primarily active in the medical device industry.

The main competitors of Masimo Corp in the market include companies such as Philips Healthcare, Nihon Kohden Corporation, and Smiths Medical.

Masimo Corp is a leading global medical technology company specializing in noninvasive patient monitoring. Founded in 1989 by Joe Kiani, the company has a rich history of innovation and advancements in the healthcare industry. Masimo Corp's core business revolves around developing and manufacturing advanced monitoring technologies, including pulse oximeters and signal extraction technology. With its commitment to improving patient outcomes and reducing healthcare costs, Masimo Corp has revolutionized the way healthcare professionals monitor patients' vital signs. Today, it is recognized as a trusted name in the medical device industry, providing innovative solutions that enhance patient care and safety worldwide.

Masimo Corp has achieved several significant milestones. Some noteworthy accomplishments include the development of breakthrough technologies in noninvasive patient monitoring, such as SET® pulse oximetry. The company has also received numerous awards and recognition for its innovative products and contributions to the healthcare industry. Masimo Corp has successfully expanded its global presence and formed strategic partnerships with leading healthcare organizations worldwide. Additionally, the company has consistently shown strong financial performance and steady revenue growth over the years. Overall, Masimo Corp continues to make strides in advancing patient care through its cutting-edge technologies and industry leadership.

Masimo Corp is primarily present in various countries and regions across the globe. Some notable markets where the company operates include the United States, European countries like Germany, France, and the United Kingdom, as well as Asian countries including Japan and China. Masimo Corp's global presence enables it to provide its innovative healthcare solutions, including noninvasive patient monitoring technologies, to healthcare facilities and professionals worldwide.

Masimo Corp represents a strong commitment to improving patient outcomes and reducing healthcare costs through innovative medical technologies. The company values include a dedication to patient safety, quality, and continuous improvement. Masimo's corporate philosophy revolves around providing noninvasive monitoring solutions that enable clinicians to make more informed decisions, enhance patient care, and optimize workflows. By combining advanced sensor and signal processing technologies, Masimo Corp strives to address the evolving needs of the medical community. The company's focus on research and development, as well as collaboration with healthcare professionals, reinforces its commitment to pioneering advancements in medical monitoring to benefit patients worldwide.

Analysts currently set an average price target of 180,21 USD for the Masimo stock (median: 183,60 USD), implying +0,1 % versus the latest price. The consensus is based on 16 analyst ratings.

Masimo Prezzi Obiettivo Analisti 2026

15 analysts currently rate the Masimo stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Masimo to generate revenue of 1,63 miliardi USD and earnings per share of 5,93 USD.

Masimo Prezzi Obiettivo Analisti 2026

Converted at the current exchange rate, the Masimo share trades at 156,33 EUR (179,95 USD).

The Masimo share (MASI) is listed on 8 stock exchanges, including: NYSE (MASI), NASDAQ (MASI), Frankfurt (3M4.F), München (3M4.MU), Düsseldorf (3M4.DU), London (0JZ2.L), London (0JZ2.L), SIX (Zürich) (3M4.SW).

Masimo Corporation is a leading provider of medical diagnostic and monitoring technologies that aim to make patient care safer and more effective. The company is headquartered in California and operates offices worldwide. Masimo's business model can be roughly divided into three areas: 1. Products and technologies Masimo offers a wide range of medical devices and technologies, including pulse oximeters for monitoring oxygen saturation in the blood, capnographs for monitoring end-tidal carbon dioxide concentration, as well as patient monitors and control systems. A highlight is Masimo's Signal Extraction Technology (SET), which is used in almost all of the company's products. SET uses a special algorithm to filter signals from skin color, movement, and other external sources of interference, allowing for accurate measurements. Additionally, Masimo has developed other innovative technologies, such as automatic measurement of hemoglobin levels, which can lead to improved patient outcomes. 2. Services Masimo also offers various services, such as installation, training, and technical support for its products. Furthermore, the company has entered into partnerships with other companies such as Apple and Philips to jointly develop innovative solutions for patient monitoring. 3. Research and development Masimo invests heavily in the research and development of new products and technologies. The company has filed numerous patents and successfully implemented them. By collaborating with clinics and universities, Masimo ensures that its products have informative features and high quality that meet the needs of patients and medical professionals. Overall, Masimo's business model is designed to make healthcare safer and more effective by developing innovative products and technologies, and by providing services and support to its customers. The wide range of products and technologies, as well as the investments in research and development, indicate that Masimo will continue to play an important role in the medical industry in the future.

Il attesa fatturato di Masimo ammonta a 1,63 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Masimo ammonta a 321,33 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Masimo è attualmente 30,35. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Masimo.

Il rapporto prezzo/fatturato (P/S) di Masimo è attualmente 5,99. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Masimo.

Il Quality Score AlleAktien per Masimo è 4/10.

L'ISIN di Masimo è US5747951003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Masimo è 578074. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Masimo è MASI. Con questo simbolo di borsa vengono negoziate le azioni Masimo in borsa.

Il rendimento da dividendo attuale di Masimo è 0,56 %.

Masimo ha pagato dividendi ogni anno negli ultimi 0 anni.

Masimo è assegnato al settore 'Sanità'.

Per ricevere l'ultimo dividendo di Masimo del per un importo di 1 USD, dovevi avere il titolo nel tuo portafoglio prima della data di stacco il .

L'ultimo dividendo è stato distribuito il .

I dividendi di Masimo sono distribuiti in USD.